A nationwide target trial emulation in US veterans with type 2 diabetes found that semaglutide initiation was associated with a twofold increased risk of nonarteritic anterior ischemic optic neuropathy...
An extensive Danish population-based study compared sodium-glucose cotransporter-2 inhibitors with glucagon-like peptide-1 receptor agonists to clarify their relative impact on diabetic foot disease, an...
A large observational cohort study published in Annals of Internal Medicine examined the effectiveness of statin therapy for primary prevention in adults with type 2 diabetes stratified by predicted 10-year...
A new real-world study evaluates whether GLP-1 receptor agonists, commonly prescribed for diabetes and obesity, are associated with a reduced risk of progression from monoclonal gammopathy of undetermined...
A multicenter trial conducted in China found that an artificial intelligence–based insulin clinical decision support system provided glycemic outcomes comparable to standard therapy administered by senior...
In a large real-world cohort study comparing semaglutide with metformin, investigators found no significant difference in the risk of incident urinary stone disease. Despite meaningful reductions in BMI...
As the clinical use of GLP-1 receptor agonists (RA) expands beyond diabetes and obesity, clinicians must balance emerging cardiometabolic and organ-specific benefits with the challenges of persistent...
In the phase 3 QWINT-1 trial, efsitora achieved noninferior reductions in glycated hemoglobin compared with once-daily insulin glargine over 52 weeks, with similar fasting glucose outcomes.
